跳至主要内容
临床试验/NCT05702385
NCT05702385撤回不适用

Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Biological Dynamic's Exo-PDAC Test: A CPV® Randomized Controlled Trial

Qure Healthcare, LLC2 个研究点 分布在 1 个国家开始时间: 2023年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
2
主要终点
CPV-measured variation in evidence based decisions between control and intervention arms

研究概览

简要总结

This is a national-level research study of oncologists, interventional gastroenterologists, and primary care providers. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care indications.

详细描述

The results of this study could contribute to improved quality of care for patients by encouraging better care practices and adherence to evidence-based guidance. The data from this study will be submitted to a national journal for publication. The study plans to enroll up to 250 physicians.

Upon consenting and agreeing to participate in this study, participants will be asked to care for 3 simulated patient cases, known as Clinical Performance and Value Vignettes (CPV®). CPV®s describe patients physicians typically encounter in their daily practice and are not meant to be difficult. In each vignette, physicians are asked to share their expected care through 5 domains: 1) history, 2) physical exam, 3) diagnostic workup, 4) diagnosis and 5) treatment and follow-up. Each case takes approximately 15-20 minutes to complete and we estimate the time commitment for each round of CPV® administration to be approximately 45 - 60 minutes. All responses to the cases will be completed online and will be kept confidential. Over 2 CPV® administration rounds, the total time to care for the simulated patients is estimated at 1.5-2 hours.

If physicians are randomized to an intervention group in this study, they will receive educational materials on a novel diagnostic test after the first round of CPV® administration. They are asked to review these materials before moving to the next CPV® administration round. The time to review educational materials is estimated to be approximately 15 minutes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Board-certified for at least two years
  • Averaging at least 20 hours per week of clinical and patient care duties over the last six months
  • Routinely evaluate patients at risk for pancreatic cancer in their practice
  • Practicing in the U.S.
  • English speaking
  • Access to the internet
  • Informed, signed, and voluntarily consented to be in the study

排除标准

  • Non-English speaking
  • Unable to access the internet
  • Not practicing in the U.S.
  • Not averaging at least 20 hours per week of clinical or patient care duties over the last six months
  • Previous exposure to the test
  • Do not voluntarily consent to be in the study

结局指标

主要结局

CPV-measured variation in evidence based decisions between control and intervention arms

时间窗: [4 months]

Measure of the difference in number of evidence-based decisions made by intervention physicians versus control physicians, while controlling for physician and practice characteristics, between rounds 1 and 2.

CPV-measured variation in evidence based decisions between intervention arms

时间窗: [4 months]

Measure the differences in amount of evidence-based decisions made by intervention group one physicians versus intervention group two physicians to assess whether the choice to order the test impacts the overall patient care and outcomes.

CPV-measured change in treatment Quality

时间窗: [4 months]

Measure of the difference in quality of overall diagnostic scores between control physicians using standard of care diagnostic tools and intervention physicians using the diagnostic test.

Clinical Performance and Value (CPV)-measured variation in Assessment

时间窗: [4 months]

Measure variation in the number and quality of clinical decisions among practicing oncologists, primary care physicians, and interventional gastroenterologists in the assessment, surveillance, and management of patients at high risk of developing PDAC. The number and quality of clinical decisions will be measured on a scale of 0-100 where higher numbers represent closer adherence to evidence base national guidelines.

CPV-measured rate of adoption for the diagnostic test

时间窗: [4 months]

Rate of adoption of the test after receiving educational materials on the benefits of testing in patients who are at risk.

CPV-measured differences in cost of care between control and intervention arms

时间窗: [4 months]

Difference in the cost of care between control and intervention physicians (Cost will be calculated by measuring differential rates of medical interventions/levels of care selected by each arm, and multiplying by Medicare reimbursement rates for these interventions, and/or by modeling the incidence of expected complications and calculating associated costs per above).

次要结局

未报告次要终点

研究者

发起方
Qure Healthcare, LLC
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验